Powell Bradford S, Andrianov Alexander K, Fusco Peter C
PharmAthene, Inc., Annapolis, MD, USA.
Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, MD, USA.
Clin Exp Vaccine Res. 2015 Jan;4(1):23-45. doi: 10.7774/cevr.2015.4.1.23. Epub 2015 Jan 30.
Adjuvants improve the adaptive immune response to a vaccine antigen by modulating innate immunity or facilitating transport and presentation. The selection of an appropriate adjuvant has become vital as new vaccines trend toward narrower composition, expanded application, and improved safety. Functionally, adjuvants act directly or indirectly on antigen presenting cells (APCs) including dendritic cells (DCs) and are perceived as having molecular patterns associated either with pathogen invasion or endogenous cell damage (known as pathogen associated molecular patterns [PAMPs] and damage associated molecular patterns [DAMPs]), thereby initiating sensing and response pathways. PAMP-type adjuvants are ligands for toll-like receptors (TLRs) and can directly affect DCs to alter the strength, potency, speed, duration, bias, breadth, and scope of adaptive immunity. DAMP-type adjuvants signal via proinflammatory pathways and promote immune cell infiltration, antigen presentation, and effector cell maturation. This class of adjuvants includes mineral salts, oil emulsions, nanoparticles, and polyelectrolytes and comprises colloids and molecular assemblies exhibiting complex, heterogeneous structures. Today innovation in adjuvant technology is driven by rapidly expanding knowledge in immunology, cross-fertilization from other areas including systems biology and materials sciences, and regulatory requirements for quality, safety, efficacy and understanding as part of the vaccine product. Standardizations will aid efforts to better define and compare the structure, function and safety of adjuvants. This article briefly surveys the genesis of adjuvant technology and then re-examines polyionic macromolecules and polyelectrolyte materials, adjuvants currently not known to employ TLR. Specific updates are provided for aluminum-based formulations and polyelectrolytes as examples of improvements to the oldest and emerging classes of vaccine adjuvants in use.
佐剂通过调节固有免疫或促进转运与呈递来增强对疫苗抗原的适应性免疫反应。随着新疫苗的成分越来越单一、应用范围不断扩大且安全性不断提高,选择合适的佐剂变得至关重要。从功能上讲,佐剂直接或间接作用于包括树突状细胞(DC)在内的抗原呈递细胞(APC),并被认为具有与病原体入侵或内源性细胞损伤相关的分子模式(分别称为病原体相关分子模式 [PAMP] 和损伤相关分子模式 [DAMP]),从而启动传感和反应途径。PAMP 型佐剂是 Toll 样受体(TLR)的配体,可直接影响 DC,以改变适应性免疫的强度、效力、速度、持续时间、偏向性、广度和范围。DAMP 型佐剂通过促炎途径发出信号,促进免疫细胞浸润、抗原呈递和效应细胞成熟。这类佐剂包括矿物盐、油乳剂、纳米颗粒和聚电解质,由具有复杂、异质结构的胶体和分子聚集体组成。如今,佐剂技术的创新受到免疫学知识迅速扩展、包括系统生物学和材料科学在内的其他领域的交叉融合以及作为疫苗产品一部分的质量、安全、功效和认知方面的监管要求的推动。标准化将有助于更好地定义和比较佐剂的结构、功能和安全性。本文简要回顾了佐剂技术的起源,然后重新审视了聚离子大分子和聚电解质材料,这些是目前未知通过 TLR 发挥作用的佐剂。作为使用中最古老和新兴的疫苗佐剂类别改进的示例,本文还提供了铝基制剂和聚电解质的具体更新情况。